Prospective study of relevance of I-MIBG myocardial scintigraphy and clonidine GH test to distinguish Parkinson's disease and multiple system atrophy.
Fiche publication
Date publication
juin 2018
Journal
Journal of neurology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr NAMER Izzie-Jacques
Tous les auteurs :
Alves Do Rego C, Namer IJ, Marcel C, Lefebvre F, Lagha-Boukbiza O, Renaud M, Tranchant C, Anheim M
Lien Pubmed
Résumé
I-MIBG myocardial scintigraphy and clonidine growth hormone test (CGH test) may help to distinguish multiple system atrophy (MSA) from Parkinson's disease (PD). Their relevance in the first-stage parkinsonism of uncertain etiology is unknown.
Mots clés
3-Iodobenzylguanidine, Biomarkers, blood, Clonidine, blood, Diagnosis, Differential, Female, Follow-Up Studies, Heart, diagnostic imaging, Humans, Male, Middle Aged, Multiple System Atrophy, diagnosis, Parkinson Disease, diagnosis, Prospective Studies, Radionuclide Imaging, Radiopharmaceuticals, Sensitivity and Specificity
Référence
J. Neurol.. 2018 Jun 28;: